(Albany, US) DelveInsight has launched a new report on Non-Radiographic Axial Spondyloarthritis Epidemiology
DelveInsight’s ‘Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Axial spondyloarthritis (axSpA) is an umbrella term inflammatory arthritis types that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS). “Non-radiographic” means that damage to the joints is not visible on X-ray. When changes to the vertebrae (the bones of the spine) or SI joints do not show any an X-ray changes, it is known as nr-axSpA. Once the joints are affected by an X-ray, a person can be diagnosed with AS.
Non-Radiographic Axial Spondyloarthritis Epidemiology
Recent studies reported the prevalence of AS to range from 9/10,000 to 30/10,000 in the general population, depending on geographic area, study population or data source, case definition, and ascertainment methods. Heterogeneity in estimates was related to differences in females’ proportion, mean age of the sample, geographic area, year of data collection, case finding, and case ascertainment. Around 5.5 million Americans have axial spondyloarthritis (axSpA), an inflammatory form of arthritis associated with chronic lower back pain. It generally starts in people during their teens or in their twenties, or maybe in their thirties. Almost always, the disease starts before age 40. Gender-wise, axSpA is now considered an equal-opportunity offender. The current average delay to diagnosis from when symptoms start is 8.5 years, by which irreversible damage to the spine may have occurred. Also, 59% of people with axial SpA (AS) report experiencing mental health problems than 25% of those with musculoskeletal conditions overall.
Non-Radiographic Axial Spondyloarthritis Key Facts
- In a US study, Curtis et al. (n.d.) estimated the prevalence of SpA at 22.6/10,000. Among 18,757 employees of the French national utility company, 72 subjects self-reported SpA based on a medical questionnaire, and 32 subjects were classified with SpA after an interview by a rheumatologist, pelvis radiographs, and HLA-B27 testing. Seventy-five percent (75%) fulfilled ASAS axial SpA criteria, 25% fulfilled ASAS peripheral SpA criteria, and two-thirds had AS. The estimated SpA prevalence was 43/10,000.
- Costantino et al. (n.d.) reported a similar rate of progression in patients with axial SpA and having at least one SpA-affected relative. In 145 patients without radiographic sacroiliitis at inclusion, 27.3% developed radiographic sacroiliitis after 3–15 years. The Kaplan-Meier estimate of the proportion of patients who progressed to radiographic sacroiliitis was 68.5% at 15 years of follow up; however, in the analysis, patients who lost to follow up were excluded from the number of patients at risk. In addition, progression was associated with low-grade radiographic sacroiliitis at baseline, buttock pain, and absence of peripheral arthritis.
- HLA-B27 is a predictor of the development of AS in patients with IBP and is also useful for identifying patients with nr-axSpA. Although most patients (between 70% and 95%) with AS have an expression of HLA-B27, only 7–8% of HLA-B27 carriers in the general population develop AS. HLA-B27 is associated with the following disease features in patients with AS: (1) younger age at disease onset, (2) development of anterior uveitis, and (3) a positive family history of SpA.
- Typically, axSpA affects the younger SpA patient population, with an average age of symptom onset of 28 years. AxSpA consists of 2 subsets of patients: those with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS), also known as radiographic axSpA. Results from current studies indicate that approximately half of all patients with axSpA are patients with nr-axSpA.
Non-Radiographic Axial Spondyloarthritis Report Scope
- The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Report and Model provide an overview of the risk factors and global trends of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
- The report provides the segmentation of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) epidemiology
Table of content
1. Key Insights
2. Executive Summary of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
3. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
10. DelveInsight Capabilities
12. About DelveInsight
Why should you buy this report?
- The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology report will allow the user to –
- Develop business strategies by understanding the trends shaping and driving the global Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market
- Quantify patient populations in the global Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) therapeutics in each of the markets covered
- Understand the magnitude of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) population by its epidemiology
- The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
- Non-Radiographic Axial Spondyloarthritis (nrAxSpA) – Market Insights, Epidemiology and Market Forecast – 2030
- Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Pipeline Insight, 2020
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States